Authors:
Jiaping Yang, Zhenxia Ma, […], and Sheng Zhang, +2 (View all authors)
Abstract
Antibody-drug conjugate (ADC) has become the standard of treatment for metastatic urothelial cancer. Current trials generally test the combination or sequential use of antibody-drug conjugates with different targets and different chemotherapeutic reagents.
We show that in three patients with metastatic urothelial cancer who have progressed on anti-HER2 antibody-drug conjugates, two showed responses when treated with EV (the same monomethyl auristatin E-containing ADC, but with different targets).
This result showed the therapeutic potential of sequential use of ADC containing the same chemotherapeutic reagents with different targets for metastatic urothelial cancer.